- Home
- QCRH vs AUPH Comparison
QCRH vs AUPH Comparison
Compare QCRH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- AUPH
- Stock Information
- Founded
- QCRH 1993
- AUPH 1993
- Country
- QCRH United States
- AUPH Canada
- Employees
- QCRH N/A
- AUPH N/A
- Industry
- QCRH Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- AUPH Health Care
- Exchange
- QCRH Nasdaq
- AUPH Nasdaq
- Market Cap
- QCRH 1.1B
- AUPH 999.8M
- IPO Year
- QCRH 1993
- AUPH 1999
- Fundamental
- Price
- QCRH $69.65
- AUPH $7.85
- Analyst Decision
- QCRH Buy
- AUPH Strong Buy
- Analyst Count
- QCRH 3
- AUPH 2
- Target Price
- QCRH $86.67
- AUPH $11.50
- AVG Volume (30 Days)
- QCRH 93.5K
- AUPH 1.1M
- Earning Date
- QCRH 04-22-2025
- AUPH 05-12-2025
- Dividend Yield
- QCRH 0.34%
- AUPH N/A
- EPS Growth
- QCRH N/A
- AUPH N/A
- EPS
- QCRH 6.65
- AUPH 0.27
- Revenue
- QCRH $324,275,000.00
- AUPH $247,295,000.00
- Revenue This Year
- QCRH N/A
- AUPH $11.86
- Revenue Next Year
- QCRH $15.85
- AUPH $24.96
- P/E Ratio
- QCRH $10.65
- AUPH $29.71
- Revenue Growth
- QCRH N/A
- AUPH 29.20
- 52 Week Low
- QCRH $54.75
- AUPH $4.98
- 52 Week High
- QCRH $96.08
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- QCRH 57.55
- AUPH 44.68
- Support Level
- QCRH $64.64
- AUPH $7.89
- Resistance Level
- QCRH $71.01
- AUPH $8.49
- Average True Range (ATR)
- QCRH 1.50
- AUPH 0.30
- MACD
- QCRH 0.79
- AUPH -0.02
- Stochastic Oscillator
- QCRH 81.47
- AUPH 36.95
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.